CYTOKINETICS INCORPORATED - COMMON STOCK

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session

25 Mar 2024 07:15:04 By Nasdaq GlobeNewswire

Cytokinetics to Participate in March Investor Conferences

04 Mar 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day

29 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials

28 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Reports Fourth Quarter 2023 Financial Results

27 Feb 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Announce Fourth Quarter Results on February 27, 2024

13 Feb 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program

29 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten

25 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024

18 Jan 2024 12:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jan 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

27 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

26 Dec 2023 15:00:11 By Nasdaq GlobeNewswire

Cytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND

07 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Dec 2023 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND

29 Nov 2023 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

03 Nov 2023 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Reports Third Quarter 2023 Financial Results

02 Nov 2023 15:00:00 By Nasdaq GlobeNewswire